Author

E. Franchin

Listed by name: these papers carry no ORCID for this author, so different people with the same name may be mixed together.

Biology Disciplines

Click to filter author papers

Evolutionary Biology· 1 Microbiology· 1

Signature Assays, Organisms & Methods

Click to filter · or open tag

Organism:human· 2 Research Focus:drug response / drug discovery· 1 Approach:experimental assay· 1 Research Focus:phylogenetics / evolution· 1 Assay:proteomics· 1 Approach:statistical model· 1 Assay:whole-genome sequencing· 1

Frequent Co-Authors

C. Del Vecchio· 2 shared A. Crisanti· 1 shared A. Di Lorenzo· 1 shared A. Magrini· 1 shared A. Miani· 1 shared A. Romeo· 1 shared A. Spitaleri· 1 shared A. Terrinoni· 1 shared

Activity by Year

2020-2021 · peak 1/yr

Co-Author Collaboration Network

10 top collaborators · 31 mutual co-author links

Click any collaborator node to inspect or filter shared papers

Focal author (center)Selected co-authorORCID co-authorUnlinked name

Curved chords = mutual co-authorship

2 shared papersEvolutionary Biology

C. Del Vecchio

Mutual co-authors in cluster

Author profile →

2 papers

Recent·Most cited

Rapid longitudinal SARS-CoV-2 intra-host emergence of novel haplotypes regardless of immune deficiencies

L. Manuto, M. Grazioli, A. Spitaleri, P. Fontana, L. Bianco, L. Bertolotti, M. Bado, G. Mazzotti, F. Bianca, F. Onelia, G. Lorenzin, F. Simeoni, D. Lazarevic, E. Franchin, C. Del Vecchio, , S. Toppo

The paper analyzes SARS-CoV-2 genomic data from a quarantined Italian town, showing rapid intra-host emergence of novel viral haplotypes within two weeks, regardless of immune status or symptoms.

bioRxiv · Dec 22, 2021 · PreprintEvolutionary Biology

Lactoferrin as potential supplementary nutraceutical agent in COVID-19 patients: in vitro and in vivo preliminary evidences

E. Campione, C. Lanna, T. Cosio, L. Rosa, M. P. Conte, F. Iacovelli, A. Romeo, M. Falconi, C. Del Vecchio, E. Franchin, M. S. Lia, M. Minieri, C. Chiaramonte, M. Ciotti, M. Nuccetelli, , L. Bianchi

This paper investigates lactoferrin's antiviral activity against SARS-CoV-2 through in vitro and in vivo studies, showing it reduces viral RNA conversion time and inflammation markers in COVID-19 patients.

bioRxiv · Aug 11, 2020 · PreprintMicrobiology